BACKGROUND: Hepatocellular carcinoma (HCC) is one human cancer with obvious gender disparity. This study investigated the association of aberrant prolactin levels with HCC risk and the potential impacts on HCC of the prolactin receptor (PRLR)/Janus kinase 2 (JAK2) signaling. METHODS: Serum prolactin of 63 HCC patients and 162 subjects without HCC was measured by radioimmunoassay. The expressions of PRLR and phosphorylated JAK2 (p-JAK2) in 82 retrospectively collected HCC specimens were evaluated by immunohistochemistry and further incorporated into the survival analysis. The immunoblotting and proliferation assays were used to analyze the effects of PRLR/JAK2 signaling on liver cancer cells with prolactin treatment. RESULTS: Serum prolactin level was significantly higher in HCC patients than in controls. Hepatocellular carcinoma patients with high p-JAK2 expression had a significantly higher postoperative risk than those with low p-JAK2 expression. Moreover, results from the multivariate analysis indicated the prognostic role of p-JAK2 expression with respect to overall survival in HCC patients. In addition, the Kaplan-Meier survival curve showed that high p-JAK2 expression was associated with poor survival in HCC patients with high PRLR expression. The immunoblotting assay showed that prolactin induced the expression of both p-JAK2 and cyclin D1 in Hep-G2 cells. Importantly, the proliferative effects induced by prolactin could be effectively attenuated by adding AG490, a JAK2 inhibitor. CONCLUSIONS: Increased circulating prolactin was found in HCC patients and high p-JAK2 expression could predict poor overall survival in those patients expressing high PRLR. In addition, prolactin contributed to the proliferation of liver cancer cells through PRLR/JAK2 signaling.
BACKGROUND:Hepatocellular carcinoma (HCC) is one humancancer with obvious gender disparity. This study investigated the association of aberrant prolactin levels with HCC risk and the potential impacts on HCC of the prolactin receptor (PRLR)/Janus kinase 2 (JAK2) signaling. METHODS: Serum prolactin of 63 HCC patients and 162 subjects without HCC was measured by radioimmunoassay. The expressions of PRLR and phosphorylated JAK2 (p-JAK2) in 82 retrospectively collected HCC specimens were evaluated by immunohistochemistry and further incorporated into the survival analysis. The immunoblotting and proliferation assays were used to analyze the effects of PRLR/JAK2 signaling on liver cancer cells with prolactin treatment. RESULTS: Serum prolactin level was significantly higher in HCC patients than in controls. Hepatocellular carcinomapatients with high p-JAK2 expression had a significantly higher postoperative risk than those with low p-JAK2 expression. Moreover, results from the multivariate analysis indicated the prognostic role of p-JAK2 expression with respect to overall survival in HCC patients. In addition, the Kaplan-Meier survival curve showed that high p-JAK2 expression was associated with poor survival in HCC patients with high PRLR expression. The immunoblotting assay showed that prolactin induced the expression of both p-JAK2 and cyclin D1 in Hep-G2 cells. Importantly, the proliferative effects induced by prolactin could be effectively attenuated by adding AG490, a JAK2 inhibitor. CONCLUSIONS: Increased circulating prolactin was found in HCC patients and high p-JAK2 expression could predict poor overall survival in those patients expressing high PRLR. In addition, prolactin contributed to the proliferation of liver cancer cells through PRLR/JAK2 signaling.
Authors: S Eguchi; T Kanematsu; S Arii; M Omata; M Kudo; M Sakamoto; K Takayasu; M Makuuchi; Y Matsuyama; M Monden Journal: Br J Surg Date: 2011-01-25 Impact factor: 6.939
Authors: J Simon-Holtorf; H Mönig; H-J Klomp; A Reinecke-Lüthge; U R Fölsch; S Kloehn Journal: Exp Clin Endocrinol Diabetes Date: 2006-11 Impact factor: 2.949
Authors: Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2005 Jan-Feb Impact factor: 508.702
Authors: J M Faupel-Badger; M E Sherman; M Garcia-Closas; M M Gaudet; R T Falk; A Andaya; R M Pfeiffer; X R Yang; J Lissowska; L A Brinton; B Peplonska; B K Vonderhaar; J D Figueroa Journal: Br J Cancer Date: 2010-08-24 Impact factor: 7.640
Authors: Ana M Corbacho; Yazmin Macotela; Gabriel Nava; Jason P Eiserich; Carroll E Cross; Gonzalo Martínez de la Escalera; Carmen Clapp Journal: FEBS Lett Date: 2003-06-05 Impact factor: 4.124
Authors: Hadley J Hartwell; Keiko Y Petrosky; James G Fox; Nelson D Horseman; Arlin B Rogers Journal: Proc Natl Acad Sci U S A Date: 2014-07-21 Impact factor: 11.205
Authors: Jake E Thistle; Jessica L Petrick; Baiyu Yang; Marie C Bradley; Barry I Graubard; Katherine A McGlynn Journal: Cancer Epidemiol Date: 2018-07-06 Impact factor: 2.984
Authors: Mark G Anderson; Qian Zhang; Luis E Rodriguez; Claudie M Hecquet; Cherrie K Donawho; Peter J Ansell; Edward B Reilly Journal: BMC Cancer Date: 2021-06-09 Impact factor: 4.430
Authors: Adrián Ramírez de Arellano; Edgar I Lopez-Pulido; Priscila A Martínez-Neri; Ciro Estrada Chávez; Renee González Lucano; Mary Fafutis-Morris; A Aguilar-Lemarroy; José F Muñoz-Valle; Ana Laura Pereira-Suárez Journal: Cancer Cell Int Date: 2015-09-04 Impact factor: 5.722